The presented data are in line with what I expected — and very favorable.
Will Anavex 2-73 be a “cure” for Alzheimer’s? No indication of that from the presented data.
But the trend lines of cognition and awareness and other Alzheimer’s disability markers are all favorable. Over the longer periods of the studies, those quantified and measured factors either remained lateral (little changed), or improved. They didn't decline (unique).
Nothing like this in any pharmacy’s drug shelves. No existing (or even experimental) drug other then A-2-73 has been able to stabilize or improve Alzheimer’s mental factors. Current Standard of Care (SOC) drugs give merely a few weeks or months of reduced symptoms, merely slowing for a period the ever steeper descent into disability and death.
Anavex has no competition. These early clinical data show conclusively that Anavex 2-73 is both safe (absent, few, or inconsequential side effects; compared to symptoms being suppressed), and chronically effective — favorable trend lines continued throughout therapy periods; even becoming more favorable toward dosing end-periods for some factors.
What might all of this mean?
1. Because A2-73 demonstrates efficacy, stabilized or increased cognitive factors, current SOC drugs no longer could be considered “standard.” There is not a shred of evidence indicating Anavex 2-73 won’t, soon enough (sooner will be better) become the worldwide Standard of Care for Alzheimer’s. Unlike anything available today, it doesn’t merely slow for a time the progression of Alzheimer’s symptoms, it stabilizes or improves them.
2. Because A2-73 has no side effects of consideration, its demonstrated safety will allow its approval by the FDA. It demonstrably treats Alzheimer’s, with safety.
3. The data strongly suggest that administration of Anavex 2-73 at the very first symptomatic indications of Alzheimer’s would keep symptoms from developing to further, more debilitating stages of the disease. With this, A2-73 could be prescribed for every middle-aged or older person showing any preliminary Alzheimer’s symptom (“Hey, what’s our neighbor’s name again?”). No, Anavex 2-73 will not be an Alzheimer’s cure. But it very strongly (to me) appears to be a powerful prophylactic, a preventative treatment that can keep millions from descending into the cognitive hell of the full-blown disease.
The market for Alzheimer’s prophylaxis and treatment is gigantic. Presently, there is no reason Anavex won’t be the sole, successful factor in addressing the problem.
I await similar studies and results for other central nervous system (CNS) diseases, such as Parkinson’s disease, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s Disease). The are in vitro (test tube) and in vivo (in cells, mostly in lab animals) that Anavex 2-73 will be profoundly therapeutic for these conditions, too. (It already works for Rett’s Syndrome and some forms of epilepsy.)
Lastly, there are very preliminary lab indications that Anavex 2-73, or similar analogues in the Anavex pipeline, can treat cancers and a number of other human diseases.
All of that is more distantly in the future. The Anavex 2-73 clinical data presented at the CTAD conference validate its profound efficacy for Alzheimer’s. I await FDA approval of the drug. I can find no reason for that not to occur.
Market Data 
Markets 
AI
